This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Emfilermin

Merck KGaA

Drug Names(s): r-hLIF, rhuLIF, AM424

Description: Emfilermin is a recombinant human form of Leukemia Inhibitory Factor (LIF). LIF enhances the viability of nerve cells after a demyelinating insult and is an important component of the nerve cell response to environmental stressors.

Deal Structure: In January 2007, the acquisition of Serono S.A. (now Merck Serono S.A.) by Merck KGaA and the integration of the business with the former Merck KGaA Ethicals Division was completed. Merck Serono is now the division of Merck KGaA which specializes in prescription pharmaceuticals. Its North American business operates in the United States and Canada under EMD Serono.


Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug